166 related articles for article (PubMed ID: 11967565)
21. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
23. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
24. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
25. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
26. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
27. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
29. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
30. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
31. Modifications of human carboxylesterase for improved prodrug activation.
Hatfield JM; Wierdl M; Wadkins RM; Potter PM
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1153-65. PubMed ID: 18721110
[TBL] [Abstract][Full Text] [Related]
32. CPT-11 converting enzyme from rat serum: purification and some properties.
Tsuji T; Kaneda N; Kado K; Yokokura T; Yoshimoto T; Tsuru D
J Pharmacobiodyn; 1991 Jun; 14(6):341-9. PubMed ID: 1783980
[TBL] [Abstract][Full Text] [Related]
33. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
34. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
[TBL] [Abstract][Full Text] [Related]
35. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Wadkins RM; Silman I; Sussman JL; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():153-7. PubMed ID: 16289500
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases.
Takayama H; Watanabe A; Hosokawa M; Chiba K; Satoh T; Aimi N
Bioorg Med Chem Lett; 1998 Mar; 8(5):415-8. PubMed ID: 9871589
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Wu MH; Yan B; Humerickhouse R; Dolan ME
Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
[TBL] [Abstract][Full Text] [Related]
38. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P
Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839
[TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase: evidence for CPT-11 drug activation.
Wierdl M; Morton CL; Danks MK; Potter PM
Biochem Pharmacol; 2000 Apr; 59(7):773-81. PubMed ID: 10718335
[TBL] [Abstract][Full Text] [Related]
40. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
